Silvano Cominelli
Chief Executive Officer at GianCom AG
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Daniel S. Aegerter | M | 55 |
ARMADA Investment AG
ARMADA Investment AG Investment ManagersFinance ARMADA Investment AG (Armada) is an independent Swiss venture capital firm headquartered in Küsnacht, Switzerland. It was founded by Daniel S. Aegerter in 2000, after he led the merger between his US-based company, TRADEX Technologies and Ariba. | 24 years |
Hampus Thorson | M | - |
ARMADA Investment AG
ARMADA Investment AG Investment ManagersFinance ARMADA Investment AG (Armada) is an independent Swiss venture capital firm headquartered in Küsnacht, Switzerland. It was founded by Daniel S. Aegerter in 2000, after he led the merger between his US-based company, TRADEX Technologies and Ariba. | 14 years |
Martin Rechsteiner | M | - |
ARMADA Investment AG
ARMADA Investment AG Investment ManagersFinance ARMADA Investment AG (Armada) is an independent Swiss venture capital firm headquartered in Küsnacht, Switzerland. It was founded by Daniel S. Aegerter in 2000, after he led the merger between his US-based company, TRADEX Technologies and Ariba. | 12 years |
Marek Grochowski | M | - |
ARMADA Investment AG
ARMADA Investment AG Investment ManagersFinance ARMADA Investment AG (Armada) is an independent Swiss venture capital firm headquartered in Küsnacht, Switzerland. It was founded by Daniel S. Aegerter in 2000, after he led the merger between his US-based company, TRADEX Technologies and Ariba. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael D. Laufer | M | 65 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 16 years |
Kathryn L. Biberstein | F | 65 |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 7 years |
Richard Batt | M | 55 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 years |
Nancy E. Isaac | F | 62 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 8 years |
Dean MacIntosh | F | 64 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 years |
Terese Bogucki | F | - |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | - |
Jean-Pierre Gotteland | M | 59 |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 9 years |
Stephan Kiefer | M | - |
GianCom AG
GianCom AG Investment ManagersFinance GianCom AG is an independent asset management firm headquartered in Zurich, Switzerland. The firm was founded in 2017 as Acoro Asset Management AG. GianCom manages a global fundamental, concentrated long-short equity fund for various types of investors. | 3 years |
Kenneth H. Haas | M | 73 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 6 years |
Bonnie J. Stearns | F | 77 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 11 years |
Samuel L. Omaleki | M | 63 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 7 years |
Edmund J. Roschak | M | 57 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 13 years |
Andrea Buscaglia | M | 60 |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 7 years |
Cary B. Cole | M | 57 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 12 years |
Michael Studer | M | - |
GianCom AG
GianCom AG Investment ManagersFinance GianCom AG is an independent asset management firm headquartered in Zurich, Switzerland. The firm was founded in 2017 as Acoro Asset Management AG. GianCom manages a global fundamental, concentrated long-short equity fund for various types of investors. | 3 years |
Michèle Ollier | M | 66 |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 2 years |
Reto Amstalden | M | - |
GianCom AG
GianCom AG Investment ManagersFinance GianCom AG is an independent asset management firm headquartered in Zurich, Switzerland. The firm was founded in 2017 as Acoro Asset Management AG. GianCom manages a global fundamental, concentrated long-short equity fund for various types of investors. | - |
Timothy Wells | M | - |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 9 years |
Buzz Benson | M | 69 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 8 years |
Pierre E. Douaze | M | - |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | 9 years |
Michael Everett | M | 74 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 3 years |
Mary E. Russell | M | 68 |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 7 years |
James W. Fitzsimmons | M | - |
Broncus Technologies, Inc.
Broncus Technologies, Inc. Medical SpecialtiesHealth Technology Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. | 14 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 14 | 51.85% |
Switzerland | 13 | 48.15% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Silvano Cominelli
- Personal Network